FDA's Priorities for Priority Review Vouchers

The evolution of the tropical disease voucher program into a full-fledged market depends heavily on how FDA implements the program. It's not just that the agency has to show that the vouchers will actually buy something of value: the agency also has to allow them to behave like a security.

The idea of a securities market where people buy and sell the right to a faster FDA review makes plenty of people nervous.

Duke University executive-in-residence Jeffrey Moe, one of the three authors of an article in Health Affairs that first proposed a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet